Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers
Richard Rosenquist(Karolinska University Hospital), Lesley McGuffog(University of Cambridge), Annika Lindblom(Karolinska University Hospital), Antonis C. Antoniou(Weatherford College), Katja Harbst(Lund University), Daniel Barrowdale(University of Cambridge), Susan M. Domchek(University City Science Center), Per Karlsson(University of Gothenburg), Andrew Lee(University of Cambridge), Jonathan Beesley(The University of Melbourne), Brita Arver(Karolinska University Hospital), Tim Rebbeck(University of Pennsylvania), Sue Healey(QIMR Berghofer Medical Research Institute), Niklas Loman(Lund University), Penny Soucy(University of Cambridge), Maria A. Caligo(Azienda Ospedaliera Universitaria Pisana), Olga M. Sinilnikova(Hospices Civils de Lyon), Karoline Kuchenbaecker(University of Cambridge)
Cited by 0
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k